Modified peptides and their uses
OwnerKarl Kadler, Neil Bulleid +1inventors
InventorsKarl Kadler, Neil Bulleid, Gillian Ashcroft
Life of this patent
Estimating the term…
Abstract
A modified pro-α chain comprising a triple helix forming domain linked to at least an N-terminal domain, the N-terminal domain containing a polypeptide from at least part of a laminin glycoprotein or secretory leukocyte protease inhibitor. The pro-α chain may form part of a procollagen molecule that has the N-terminal domain retained. The procollagen molecule may be incorporated into collagen polymers, matrices and gels and be used for such applications as wound healing.
Claims19
A method of treating a wound or fibrotic disorder comprising administering to a subject in need of such treatment a therapeutically effective amount of a modified pro-α chain wherein the modified pro-α chain comprises at least part of a secretory leukocyte protease inhibitor wherein the at least part of a secretory leukocyte protease inhibitor is placed N-terminal to a triple helical forming domain of the pro-α chain.
A method of treating a wound or fibrotic disorder comprising administering to a subject in need of such treatment a therapeutically effective amount of a procollagen molecule comprising a trimer of pro-α chains wherein the molecule comprises SEQ ID NO:
- 27.
A method of treating a wound or fibrotic disorder comprising administering to a subject in need of such treatment a therapeutically effective amount of a procollagen molecule comprising a trimer of pro-α chains characterized in that at least one of the pro-α chains is a modified pro-α chain comprising at least a part of a secretory leukocyte protease inhibitor wherein the at least part of a secretory leukocyte protease inhibitor is placed N-terminal to a triple helical forming domain of the pro-α chain.
A method of treating a wound or fibrotic disorder comprising administering to a subject in need of such treatment a therapeutically effective amount of a collagen polymer comprising at least one modified collagen monomer, wherein said modified collagen monomer comprises at least part of a secretory leukocyte protease inhibitor placed N-terminal to a triple helical forming domain in a collagen monomer.
Dependencies are inferred from the claim text.